title: Soluble VE-cadherin in metastatic breast cancer: an independent prognostic factor for both progression-free survival and overall survival.
abstract: Patients with metastatic breast cancer (MBC) represent a heterogeneous group, with large differences in outcomes from individual patients. VE-cadherin, an endothelial-specific cadherin, was shown to promote tumour proliferation and angiogenesis. Soluble VE-cadherin has been recently associated to breast cancer progression. This study was designed to investigate the prognosis significance of soluble VE-cadherin in hormone-refractory MBC.
  
  
  
  Between 2004 and 2007, 150 patients with a fully documented history of hormone-refractory MBC were included in the prospective SEMTOF study. Serum concentrations of VE-cadherin were measured at inclusion for 141 patients and 6 weeks after the beginning of chemotherapy, using a sandwich enzyme immunoassay.
  
  
  
  The presence of high levels of serum VE-cadherin was significantly correlated to a shorter progression-free (PFS) and overall survival (OS). In a multivariate analysis along with clinical and biologic prognostic parameters, high serum VE-cadherin level was an independent adverse prognostic variable for PFS (median PFS 9.7 (IC95: 8; 11.9) vs 5.8 (IC95: 4.1; 8) months P=0.0008) and OS (median OS 34 (IC95: 26.6; 47.1) vs 14.8 (IC95: 9.3; 21.4) months P=0.0007). Moreover, VE-cadherin decrease during chemotherapy was also associated with good prognosis.
  
  
  
  Serum VE-cadherin levels correlate to poorer survival in patients with hormone-refractory MBC. As sVE-cadherin reflects tumour angiogenesis, this could have therapeutic implications for antiangiogenic treatment.
authors.affiliation: Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, Lyon F-69373, France.
authors.forename: Pauline
authors.initials: P
authors.lastname: Rochefort
authors.affiliation: Direction de la Recherche Clinique et de l'Innovation, Centre Léon Bérard, Lyon F-69373, France.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Chabaud
authors.affiliation: Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, Paris F-95005, France.
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Pierga
authors.affiliation: Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, Lyon F-69373, France.
authors.forename: Olivier
authors.initials: O
authors.lastname: Tredan
authors.affiliation: Department of Medical Oncology, Institut Curie - Hopital René Hugueneau, 35 Rue Dailly, Saint Cloud F-92210, France.
authors.forename: Etienne
authors.initials: E
authors.lastname: Brain
authors.affiliation: Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, Paris F-95005, France.
authors.forename: François-Clément
authors.initials: FC
authors.lastname: Bidard
authors.affiliation: Direction de la Recherche Clinique et de l'Innovation, Centre Léon Bérard, Lyon F-69373, France.
authors.forename: Camille
authors.initials: C
authors.lastname: Schiffler
authors.affiliation: INSERM, UMR-S 1036, Grenoble F-38054, France.|University Grenoble-Alpes, Grenoble F-38000, France.|CEA, DRF, Biosciences and Biotechnology Institute of Grenoble (BIG), Laboratory of Biology of Cancer and Infection, Grenoble F-38054, France.
authors.forename: Helena
authors.initials: H
authors.lastname: Polena
authors.affiliation: INSERM, UMR-S 1036, Grenoble F-38054, France.|University Grenoble-Alpes, Grenoble F-38000, France.|CEA, DRF, Biosciences and Biotechnology Institute of Grenoble (BIG), Laboratory of Biology of Cancer and Infection, Grenoble F-38054, France.
authors.forename: Abir
authors.initials: A
authors.lastname: Khalil-Mgharbel
authors.affiliation: INSERM, UMR-S 1036, Grenoble F-38054, France.|University Grenoble-Alpes, Grenoble F-38000, France.|CEA, DRF, Biosciences and Biotechnology Institute of Grenoble (BIG), Laboratory of Biology of Cancer and Infection, Grenoble F-38054, France.
authors.forename: Isabelle
authors.initials: I
authors.lastname: Vilgrain
authors.affiliation: Department of Medical Oncology, Centre Léon Bérard, 28 Rue Laennec, Lyon F-69373, France.
authors.forename: Thomas
authors.initials: T
authors.lastname: Bachelot
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D015820:Cadherins / Q000097:blood*; D018450:Disease Progression; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D016019:Survival Analysis; D000099152:Cadherin 5
chemical_list: D015703:Antigens, CD; D014408:Biomarkers, Tumor; D015820:Cadherins; D000099152:Cadherin 5